Supernus Pharmaceuticals, Inc. (SUPN)
NASDAQ: SUPN · Real-Time Price · USD
49.33
-0.18 (-0.36%)
Oct 10, 2025, 3:50 PM EDT - Market open
Supernus Pharmaceuticals Revenue
Supernus Pharmaceuticals had revenue of $165.45M in the quarter ending June 30, 2025, a decrease of -1.71%. This brings the company's revenue in the last twelve months to $665.13M, up 5.55% year-over-year. In the year 2024, Supernus Pharmaceuticals had annual revenue of $661.82M with 8.94% growth.
Revenue (ttm)
$665.13M
Revenue Growth
+5.55%
P/S Ratio
4.14
Revenue / Employee
$986,832
Employees
674
Market Cap
2.77B
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 661.82M | 54.30M | 8.94% |
Dec 31, 2023 | 607.52M | -59.72M | -8.95% |
Dec 31, 2022 | 667.24M | 87.46M | 15.09% |
Dec 31, 2021 | 579.78M | 59.38M | 11.41% |
Dec 31, 2020 | 520.40M | 127.64M | 32.50% |
Dec 31, 2019 | 392.76M | -16.14M | -3.95% |
Dec 31, 2018 | 408.90M | 106.66M | 35.29% |
Dec 31, 2017 | 302.24M | 87.24M | 40.57% |
Dec 31, 2016 | 215.00M | 67.54M | 45.80% |
Dec 31, 2015 | 147.47M | 54.79M | 59.12% |
Dec 31, 2014 | 92.68M | 80.66M | 671.10% |
Dec 31, 2013 | 12.02M | 10.54M | 712.09% |
Dec 31, 2012 | 1.48M | 677.00K | 84.31% |
Dec 31, 2011 | 803.00K | - | - |
Dec 31, 2010 | - | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 422.82B |
Johnson & Johnson | 90.63B |
Merck & Co. | 63.62B |
AbbVie | 58.33B |
AstraZeneca | 56.50B |
Novartis AG | 55.19B |
Eli Lilly and Company | 53.26B |
Novo Nordisk | 49.11B |
SUPN News
- 22 days ago - Supernus Pharmaceuticals: Heading In The Right Direction - Seeking Alpha
- 6 weeks ago - Supernus Pharmaceuticals to Participate in September Investor Conferences - GlobeNewsWire
- 2 months ago - Supernus Pharmaceuticals, Inc. (SUPN) Q2 2025 Earnings Call Transcript - Seeking Alpha
- 2 months ago - Supernus Announces Second Quarter 2025 Financial Results - GlobeNewsWire
- 2 months ago - Supernus Pharmaceuticals Completes Acquisition of Sage Therapeutics - GlobeNewsWire
- 2 months ago - Supernus Pharmaceuticals Announces Expiration of Hart-Scott-Rodino Waiting Period for Sage Therapeutics, Inc. Tender Offer - GlobeNewsWire
- 2 months ago - Supernus Pharmaceuticals to Announce Second Quarter 2025 Financial Results and Host Conference Call and Webcast on August 5, 2025 - GlobeNewsWire
- 3 months ago - SAGE THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Sage Therapeutics, Inc. - SAGE - Business Wire